Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefixime for switch therapy

J Hamilton-Miller1

  • 1Department of Medical Microbiology, Royal Free Hospital School of Medicine, London, UK.

Chemotherapy
|November 3, 1998
PubMed
Summary
This summary is machine-generated.

Switch therapy, or step-down therapy, transitions patients from intravenous to oral antibiotics like cefixime. This approach shows excellent clinical outcomes and significant cost savings, primarily through shorter hospital stays.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probiotics strain for credibility.

Lancet (London, England)·2000
Same author

Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis?

Biochemistry and molecular biology international·1995
Same author

[Antibiotic resistance in Haemophilus influenzae].

Enfermedades infecciosas y microbiologia clinica·1994
Same author

Antimitochondrial antibodies in primary biliary cirrhosis recognize both specific peptides and shared epitopes of the M2 family of antigens.

Hepatology (Baltimore, Md.)·1989
Same author

Ciprofloxacin resistance in methicillin- and gentamicin-resistant Staphylococcus aureus.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·1989
Same author

Methicillin-resistant Staphylococcus aureus.

The New England journal of medicine·1989
Same journal

Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy.

Chemotherapy·2026
Same journal

Pseudoprogression of a head and neck cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy: a case report and review of the literature.

Chemotherapy·2026
Same journal

Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A case series.

Chemotherapy·2026
Same journal

Efficacy and Safety Study of Different Doses of Linezolid in Combination with Bedaquiline in the Treatment of Drug-Resistant Pulmonary Tuberculosis.

Chemotherapy·2026
Same journal

Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?

Chemotherapy·2026
Same journal

Expression of Concern.

Chemotherapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Health Economics

Background:

  • Switch therapy, or step-down therapy, involves transitioning patients from intravenous to oral antibiotics.
  • This strategy is employed once a patient's condition improves and pathogen susceptibility is known.
  • Cefixime, an oral third-generation cephalosporin, is a key candidate for this therapeutic approach due to its favorable efficacy and safety profile.

Purpose of the Study:

  • To evaluate the clinical outcomes and cost-effectiveness of switch therapy using cefixime for serious infections.
  • To highlight the potential of cefixime in reducing hospital stay duration.
  • To emphasize the need for clear guidelines and increased awareness regarding switch therapy.

Main Methods:

  • Review of preliminary studies on switch therapy with cefixime.

Related Experiment Videos

  • Analysis of clinical outcomes in patients treated with cefixime switch therapy.
  • Assessment of cost benefits, focusing on length of hospital stay.

    • Main Results:

    • Preliminary studies indicate excellent clinical outcomes with cefixime switch therapy after 2-3 days for various serious infections.
    • Significant cost benefits were observed, particularly a reduction in the length of hospital stays.
    • Cefixime demonstrates a good efficacy and safety profile suitable for oral step-down therapy.

    Conclusions:

    • Switch therapy to cefixime is a viable and effective strategy for managing serious infections.
    • This approach offers substantial economic advantages by shortening hospitalizations.
    • Development of clear clinical guidelines and enhanced hospital-wide awareness is crucial for optimal implementation of switch therapy.